IL2 and primary cutaneous T-cell non-Hodgkin lymphoma: While these routes are still under investigation and their biologically regulation is less understood, both IL2-targeting and, most profusely, the CAM pathway are being explored for drug delivery in the context of therapy-refractory cutaneous T-cell lymphoma (IL2-mediated) as well as antioxidative, anti-inflammatory approaches [43,45].